Skip to main content

Table 3 Prevalence of mutational signatures

From: Mutational signatures among young-onset testicular cancers

Signature

20–29

30–39

 > 40

p-value

(20–29 vs. > 40)

p-value

(30–39 vs. > 40)

p-value

(continuous age)

Signature 1

16 (40%)

16 (39%)

2 (10%)

0.12

0.047*

0.14

Signature 3

35 (88%)

34 (83%)

18 (90%)

0.69

0.41

0.54

Signature 6

17 (42%)

13 (32%)

10 (50%)

0.40

0.15

0.55

Signature 8

14 (35%)

14 (34%)

0 (0%)

NA

NA

0.020*

Signature 11

3 (8%)

2 (5%)

6 (30%)

0.10

0.026*

0.010*

Signature 13

5 (12%)

6 (15%)

3 (15%)

0.64

0.73

0.29

Signature 15

11 (28%)

11 (27%)

5 (25%)

0.43

0.78

0.51

Signature 16

16 (40%)

16 (39%)

14 (70%)

0.034*

0.032*

0.13

Signature 19

12 (30%)

17 (41%)

5 (25%)

0.85

0.23

0.80

Signature 20

6 (15%)

8 (20%)

3 (15%)

0.83

0.73

0.90

Signature 24

21 (52%)

17 (41%)

9 (45%)

0.69

0.80

0.55

Signature 26

2 (5%)

6 (15%)

4 (20%)

0.22

0.84

0.49

Signature 29

14 (35%)

12 (29%)

2 (10%)

0.039*

0.085

0.036*

Signature 30

28 (70%)

23 (56%)

10 (50%)

0.23

0.82

0.32

  1. Prevalence of COSMIC mutational signatures among testicular tumors diagnosed at ages 20–29 (n = 40), 30–39 (n = 41), and age 40 or older (n = 20). Entries are number (proportion) of cases with a signature present above a threshold of 6% in each age of onset group. Differences in signatures by age at onset groups were tested using a logistic regression model * indicates statistical significance at a .05 level